Financial Review: Titan Pharmaceuticals (TTNP) vs. Mymetics (MYMX)

Titan Pharmaceuticals (NASDAQ:TTNP) and Mymetics (OTCMKTS:MYMX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.


This table compares Titan Pharmaceuticals and Mymetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Titan Pharmaceuticals -168.73% -878.37% -119.79%
Mymetics -355.47% N/A -55.35%

Institutional and Insider Ownership

5.7% of Titan Pharmaceuticals shares are held by institutional investors. Comparatively, 0.8% of Mymetics shares are held by institutional investors. 6.5% of Titan Pharmaceuticals shares are held by company insiders. Comparatively, 54.2% of Mymetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Titan Pharmaceuticals has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Mymetics has a beta of -3.16, indicating that its stock price is 416% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Titan Pharmaceuticals and Mymetics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Titan Pharmaceuticals 0 1 0 0 2.00
Mymetics 0 0 0 0 N/A

Titan Pharmaceuticals currently has a consensus target price of $2.00, suggesting a potential upside of 733.33%. Given Titan Pharmaceuticals’ higher probable upside, analysts clearly believe Titan Pharmaceuticals is more favorable than Mymetics.

Earnings & Valuation

This table compares Titan Pharmaceuticals and Mymetics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Titan Pharmaceuticals $220,000.00 85.06 -$14.30 million ($0.70) -0.34
Mymetics $1.71 million 9.73 -$4.64 million N/A N/A

Mymetics has higher revenue and earnings than Titan Pharmaceuticals.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.

About Mymetics

Mymetics Corporation, a vaccine company, focuses on developing vaccines for infectious diseases primarily in Switzerland. The company's product pipeline includes vaccine candidates, such as HIV-1/AIDS, intra nasal influenza, malaria, chikungunya, herpes simplex virus, and the respiratory syncitial virus (RSV) vaccine. It has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative; the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; RSV Corporation for developing the RSV vaccine; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit